Aurion Biotech Says Co Achieves All Primary, Secondary, And Exploratory Endpoints In Aurn001 Phase 1/2 Clara Trial At 12 Months
Oct 18 (Reuters) - Aurion Biotech Inc AURN.N:
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.